1 Correction to: Clinical Drug Investigation (2019) 39:805–819 https://doi.org/10.1007/s40261-019-00826-0

The original version of this article unfortunately contained some mistakes. The corrected details are provided below:


Page 805:The title of the article, which previously read:


“Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features”


should read:


“Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features”


Running header, which previously read:


“Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes”


should read:


“Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes”


Page 805, Abstract:The beginning of the first sentence, which previously read:


“Glucagon-like peptide-1 receptor analogues/agonists”


should read:


“Glucagon-like peptide-1 receptor agonists”


Page 805, Section 1, para 2, end of the second sentence, which previously read:


“thereby providing the rationale for developing GLP-1 receptor analogues/agonists (GLP-1RAs) to treat T2D [3].”


Should read:


“thereby providing the rationale for developing GLP-1 receptor agonists (GLP-1RAs) to treat T2D [3].”


Page 811, Section 4, para 2, end of the first sentence, which previously read:


“some other glucose-lowering drugs (most frequently semaglutide vs sitagliptin or insulin glargine [28–32]) [Table 3]”


Should read:


“some other glucose-lowering drugs (most frequently semaglutide vs sitagliptin or insulin glargine [28–32]) [Table 3].”


Page 817, first column, last para, first sentence, which previously read:


“GLP-1RAs must be administered subcutaneously, which is disadvantage relative to the convenient oral administration of most other classes of glucose-lowering drugs.”


Should read:


“GLP-1RAs must be administered subcutaneously, which is a disadvantage relative to the convenient oral administration of most other classes of glucose-lowering drugs.”


Captions of Table 1 (page 807), Table 2 (page 808), Table 3 (page 812), Table 4 (page 814), Table 5 (page 815) and Table 6 (page 816): The part of the table caption, which previously read:


“glucagon-like peptide-1 receptor analogues”


should read:


“glucagon-like peptide-1 receptor agonists”


The following section was inadvertently omitted:


Acknowledgements The author thanks Prof. John Wilding, Obesity & Endocrinology Research, Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UK for his assistance in preparing this review.


The original article has been corrected.